Abstract
In this study, the in vivo pharmacokinetics and pharmacodynamics of a novel recombinant human erythropoietin (rhEPO) Fc fusion protein, rhEPO-Fc, were studied in both rodents and rhesus monkeys. Animal models of anemia induced by irradiation, cyclophosphamide and partial renal ablation were used to evaluate therapeutic effects of rhEPO-Fc. We have demonstrated that serum half-life of rhEPO-Fc was 29.5 to 38.9 h at doses of 8, 25, 80 µg/kg in rhesus monkeys and 35.5 to 43.5 h at doses of 16, 50, 160 µg/kg in rats. In anemia animal models, rhEPO-Fc dose-dependently (7.5–30.0 µg/kg in mice, 5.4–21.4 µg/kg in rats and 5.0–10.0 µg/kg in rhesus monkeys) increased reticulocyte level, followed by an increase of RBC count, hemoglobin and hematocrit levels. At reduced intervention frequency of weekly treatments, rhEPO-Fc showed similar hematopoietic effects as compared with rhEPO given three times a week. These results indicated that rhEPO-Fc could potentially be used in treatment of anemia and warrants future clinical trials.
Highlights
Erythropoietin (EPO) is a glycoprotein that stimulates the production of erythrocytes [1,2]
Pharmacokinetics To evaluate pharmacokinetic behavior of the recombinant human EPO (rhEPO)-Fc fusion protein in vivo, both single and repeated rhEPO-Fc injections were conducted in both rats and rhesus monkeys
To maintain its erythropoietic property and to avoid unpredicted risk of immunogenicity in clinical application, no mutation was introduced into EPO in our rhEPO-Fc fusion protein
Summary
Erythropoietin (EPO) is a glycoprotein that stimulates the production of erythrocytes [1,2]. It promotes proliferation, differentiation and maturation of erythroid progenitor cells, and inhibits their apoptosis [3]. Since initial clinical usage of rhEPO-a in the 1980s, clinicians quickly recognized the need of frequent administration as one of major drawbacks of the drug. This imposes a burden on both patients and health care providers, as in vivo half-lives of rhEPO-a and rhEPO-b administered intravenously or subcutaneously in humans are only about 8.5 and 17 hours respectively [9,10]. There has been a longstanding need to develop recombinant EPO analogs with longer in vivo half-lives
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
